Track the HALOZYME THERAPEUTICS INC stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €11.7bn. The latest transaction was filed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Torley Helen. The full history is accessible without an account.
14
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HALOZYME THERAPEUTICS INC Buy (bullish), based on 9 analysts. Average price target: US$99.56.
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,470 of 29,063 companies
58.5
score / 100
Value
40
Quality
77
FCF yld3.0%
Earn yld2.6%
EV/EBITDA24.8x
ROE174%
Gross mgn84%
Net mgn23%
Debt/EBITDA3.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
HALOZYME THERAPEUTICS INC es una empresa biofarmacéutica centrada en el desarrollo de terapias basadas en enzimas para mejorar la administración de fármacos. Cotiza en el NASDAQ bajo el símbolo HALO.